FDA Drug recall D-0380-2019
Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Mary…
- FDA Drug
- Class II
- terminated
- Published 2019-01-23
On 2019-01-23 the FDA classified a Class II recall of Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Mary… by Lupin Pharmaceuticals, citing CGMP Deviation; manufacturing batch record could not be located.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-0380-2019 |
| Classification | Class II |
| Status | terminated |
| Initiated | 2019-01-07 |
| Published | 2019-01-23 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Lupin Pharmaceuticals |
| Distribution | US |
Product
Cephalexin for Oral Suspension USP, 250mg/5mL, 200 mL (when mixed), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland, Manufactured by: Lupin Limited, Mandideep, India ---- NDC 68180-0124-02
Reason
CGMP Deviation; manufacturing batch record could not be located
Identifiers
| code_info | lot # F602820, Expiry December 2019 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0380-2019%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.